Benzinga.com: Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Nasdaq: SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Nasdaq: GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis
GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis
Morningstar: Pfizer to Advance Eczema Treatment to Phase 3 After Phase 2 Study Hits Goal
Pfizer said a Phase 2 study of tilrekimig met its key goals in adults with moderate to severe atopic dermatitis, the most common form of eczema, and that it plans to accelerate the drug candidate into ...
Pfizer to Advance Eczema Treatment to Phase 3 After Phase 2 Study Hits Goal
Nasdaq: Tonix Pharmaceuticals Announces Upcoming FDA PDUFA Goal Date for TNX-102 SL and Positive Phase 1 Results for TNX-1500
Tonix Pharmaceuticals Announces Upcoming FDA PDUFA Goal Date for TNX-102 SL and Positive Phase 1 Results for TNX-1500
Morningstar: San Antonio Sets Unified Goal to Increase Educational Attainment to 45% by 2030
San Antonio Sets Unified Goal to Increase Educational Attainment to 45% by 2030